Up­dat­ed: Mod­er­na rounds out 2022 with $18.4B in vac­cine sales, boosts R&D bud­get for 2023

Mod­er­na CEO Stéphane Ban­cel is revving the en­gines go­ing in­to 2023, with a whop­ping $4.5 bil­lion R&D bud­get and a new pri­or­i­ty re­view vouch­er.

The com­pa­ny’s full-year sales to­taled $18.4 bil­lion, it an­nounced on Mon­day, falling shy of the chief ex­ec­u­tive’s pre­vi­ous $21 bil­lion pro­jec­tions. Ban­cel cit­ed de­liv­ery de­lays, short-term sup­ply short­ages and a “very com­plex third quar­ter from a man­u­fac­tur­ing stand­point” up­on low­er­ing the guid­ance last quar­ter, while promis­ing that the com­pa­ny is “in a much bet­ter place” for 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER